Develops neuroplastogens—novel serotonergic compounds designed to stimulate neural circuit growth and remodeling—using a computationally-enhanced drug discovery platform. These therapies aim to provide scalable, non-hallucinogenic treatments for mood disorders, addiction, and neurological conditions, overcoming the accessibility and cost challenges associated with traditional psychedelics like psilocybin.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for mood disorders, addiction, and neurological conditions, such as traditional antidepressants and psychedelics like psilocybin, often have limitations in scalability, accessibility, and side effects. Traditional psychedelics require specialized treatment providers, have high costs, and face regulatory constraints, while SSRI medications can have unfavorable side effects like loss of libido, weight gain, and insomnia.
Solution
Psylo is a biotechnology company focused on developing neuroplastogens, a novel class of therapies designed to restore brain function by stimulating the growth and remodeling of neural circuits. Psylo utilizes a computationally-enhanced drug discovery platform to design and develop widely accessible, rapid-acting serotonergic agents without the side effects and scalability challenges of psilocybin. These next-generation therapeutics are designed to elicit neuronal remodeling without causing hallucinatory effects, offering a potentially safer and more effective treatment option. The company's objective is to create bioavailable medications, similar to traditional antidepressants, but with a faster onset of action and fewer side effects.
Target Audience
The primary target audience includes individuals suffering from mood disorders, addiction, and neurological conditions, as well as healthcare providers seeking scalable, accessible, and effective treatment options with fewer side effects than traditional antidepressants or supervised psychedelic therapies.
Features
- Computationally-enhanced drug discovery platform for optimized pharmacological profiles
- Development of non-hallucinogenic 5-HT2A agonists that activate serotonin receptors without psychoactive effects
- Preclinical studies demonstrating antidepressant effects and the ability to promote neuroplasticity
- Novel compounds designed to be safely administered at home without clinical supervision
- Targeting a variety of mental illnesses, including mood disorders, addiction, and neurological conditions